GlassScriptPhysician profile
Richard B Bymaster
NPI 1689623696
$22,600.06
in general payments reported to CMS, 2019-2025
64 companies · $2,579 in 2025
The $2,579 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,842 · 2020: $3,253 · 2021: $3,677 · 2022: $2,678 · 2023: $2,608 · 2024: $2,963 · 2025: $2,579.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,021 · Education: $129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,021.47 |
| Education | $128.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,403.12 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $2,677.29 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Amgen INC. | $2,158.03 | 2019-2025 | Otezla, Repatha, Otezla |
| Pfizer INC. | $1,687.75 | 2019-2025 | |
| Abbvie INC. | $1,200.86 | 2019-2025 | Vraylar, Ubrelvy, Linzess |
| Lilly USA, LLC | $999.30 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $839.57 | 2019-2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $823.62 | 2019-2022 | |
| Glaxosmithkline, LLC. | $758.11 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Sanofi-Aventis U.S. LLC | $743.05 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $717.39 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Amarin Pharma, INC. | $501.74 | 2019-2022 | |
| Eisai INC. | $477.05 | 2020-2022 | |
| Astellas Pharma US INC | $473.16 | 2019-2024 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $405.58 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Bymaster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.